Literature DB >> 15182218

SSRIs and intraocular pressure modifications: evidence, therapeutic implications and possible mechanisms.

Ciro Costagliola1, Francesco Parmeggiani, Adolfo Sebastiani.   

Abstract

SSRIs are the most commonly prescribed antidepressant drugs, in part because of their favourable safety profile compared with older antidepressants. However, the widespread use of SSRIs leads to an increased occurrence of rare adverse effects. This review, based on data from published experimental research, clinical studies and case reports, describes the role of serotonin in the control of intraocular pressure (IOP) and the evidence for IOP modifications in patients receiving SSRIs. In a small percentage of patients with depression, the cause of SSRI withdrawal has been the occurrence of ill-defined visual disturbances. It can be speculated that in some of these patients, the iatrogenic ocular alterations could have been due to changes in IOP. There have also been a limited number of case reports of acute attacks of glaucoma occurring during treatment with SSRIs. Although causality is not exactly specified, the relationship between SSRIs and this ocular adverse event is strongly implied. Nevertheless, in a small clinical study assessing the effect of a single dose of fluoxetine on IOP, the drug was shown to increase this parameter, although the effect was asymptomatic. The clinical signs of unexpected adverse drug effects are often disregarded, with the exception of those characterised by serious symptoms (such as acute angle-closure glaucoma in the case of IOP modifications). Also, the distribution of iridocorneal angle configurations in the general population implies that an adverse effect on IOP will be pauci- or asymptomatic in most patients (intermittent, sub-acute or progressive angle-closure glaucoma). As a result, it is likely that the incidence of SSRI-related IOP modifications is underestimated. Until the involvement of SSRIs in IOP modifications is better understood, ophthalmological consultations should be considered before starting and during treatment with any SSRI in patients with glaucomatous risk factors, especially those who are elderly.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15182218     DOI: 10.2165/00023210-200418080-00001

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  70 in total

1.  Acute angle closure glaucoma associated with paroxetine.

Authors:  T Eke; A K Bates
Journal:  BMJ       Date:  1997-05-10

2.  Evidence-based health policy--lessons from the Global Burden of Disease Study.

Authors:  C J Murray; A D Lopez
Journal:  Science       Date:  1996-11-01       Impact factor: 47.728

Review 3.  The safety of fluoxetine--an update.

Authors:  G L Cooper
Journal:  Br J Psychiatry Suppl       Date:  1988-09

Review 4.  Molecular, pharmacological and functional diversity of 5-HT receptors.

Authors:  Daniel Hoyer; Jason P Hannon; Graeme R Martin
Journal:  Pharmacol Biochem Behav       Date:  2002-04       Impact factor: 3.533

5.  Electron microscopy of the indoleamine-accumulating neurons in the retina of the rabbit.

Authors:  B Ehinger; I Holmgren
Journal:  Cell Tissue Res       Date:  1979-03-19       Impact factor: 5.249

6.  On pseudofacility.

Authors:  H Goldmann
Journal:  Bibl Ophthalmol       Date:  1968

7.  Antidepressant drug interactions in the elderly. Understanding the P-450 system is half the battle in reducing risks.

Authors:  R J Cadieux
Journal:  Postgrad Med       Date:  1999-11       Impact factor: 3.840

Review 8.  Molecular biology of 5-HT receptors.

Authors:  F G Boess; I L Martin
Journal:  Neuropharmacology       Date:  1994 Mar-Apr       Impact factor: 5.250

9.  Compliance with antidepressant medication in the treatment of major depressive disorder in primary care: a randomized comparison of fluoxetine and a tricyclic antidepressant.

Authors:  C Thompson; R C Peveler; D Stephenson; J McKendrick
Journal:  Am J Psychiatry       Date:  2000-03       Impact factor: 18.112

Review 10.  International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin).

Authors:  D Hoyer; D E Clarke; J R Fozard; P R Hartig; G R Martin; E J Mylecharane; P R Saxena; P P Humphrey
Journal:  Pharmacol Rev       Date:  1994-06       Impact factor: 25.468

View more
  19 in total

Review 1.  Non-steroidal drug-induced glaucoma.

Authors:  M R Razeghinejad; M J Pro; L J Katz
Journal:  Eye (Lond)       Date:  2011-06-03       Impact factor: 3.775

2.  Reports of acute angle closure glaucoma-related adverse events with SSRIs: results of a disproportionality analysis.

Authors:  Manfred Hauben; Lester Reich
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

3.  Selective serotonin reuptake inhibitor use and increased risk of cataract surgery: a population-based, case-control study.

Authors:  Jay C Erie; Scott M Brue; Alanna M Chamberlain; David O Hodge
Journal:  Am J Ophthalmol       Date:  2014-03-14       Impact factor: 5.258

Review 4.  Ocular adverse effects of common psychotropic agents: a review.

Authors:  Sami Richa; Jean-Claude Yazbek
Journal:  CNS Drugs       Date:  2010-06       Impact factor: 5.749

5.  Evaluation of the effects of duloxetine treatment on anterior segment parameters by optical coherence tomography.

Authors:  Murat A Özer; İlker F Sarı; Hakan Koç; Nurçe Ç Yavuz; Serkan Özen; Fazıl Kulaklı
Journal:  Int Ophthalmol       Date:  2022-07-07       Impact factor: 2.031

6.  [Is the flashlight test of any use in primary care for detecting eyes with shallow anterior chamber?].

Authors:  Antonio Trueba Castillo; Luis Javier Negredo Bravo; Cristina Cárdenas Valencia; María Josefa Gil de Gómez Barragán; Rosa Ana Arribas García
Journal:  Aten Primaria       Date:  2009-10-01       Impact factor: 1.137

Review 7.  A review of systemic medications that may modulate the risk of glaucoma.

Authors:  Annie Wu; Anthony P Khawaja; Louis R Pasquale; Joshua D Stein
Journal:  Eye (Lond)       Date:  2019-10-08       Impact factor: 3.775

Review 8.  Psychotropic Drug-Induced Glaucoma: A Practical Guide to Diagnosis and Management.

Authors:  Neeranjali S Jain; Claire W Ruan; Shanil R Dhanji; Richard J Symes
Journal:  CNS Drugs       Date:  2021-02-19       Impact factor: 5.749

9.  Clinical and Rehabilitative Management of Retinitis Pigmentosa: Up-to-Date.

Authors:  Francesco Parmeggiani; Giovanni Sato; Katia De Nadai; Mario R Romano; Andrea Binotto; Ciro Costagliola
Journal:  Curr Genomics       Date:  2011-06       Impact factor: 2.236

10.  Topiramate-associated acute glaucoma in a migraine patient receiving concomitant citalopram therapy: a case-report.

Authors:  Luca Spaccapelo; Silvia Leschiutta; Claudio Aurea; Anna Ferrari
Journal:  Cases J       Date:  2009-01-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.